NCT01392443 - Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

October 14, 2010

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions

Primary Myelofibrosis (MF)Post-Polycythemia Vera (PV) MFPost-Essential Thrombocythemia (ET) MF

Interventions

DRUG

Ruxolitinib

INC424 Tablet for oral use, provided in 5 mg bottles. The dosage strength was 5 mg/tablet INC424 phosphate (free base equivalent).

Trial Locations (26)

333

Novartis Investigative Site, Taoyuan District

833

Novartis Investigative Site, Kaohsiung City

10048

Novartis Investigative Site, Taipei

51000

Novartis Investigative Site, Guangzhou

100730

Novartis Investigative Site, Beijing

200025

Novartis Investigative Site, Shanghai

210029

Novartis Investigative Site, Nanjing

215006

Novartis Investigative Site, Suzhou

250012

Novartis Investigative Site, Jinan

300020

Novartis Investigative Site, Tianjin

310003

Novartis Investigative Site, Hangzhou

430030

Novartis Investigative Site, Wuhan

610041

Novartis Investigative Site, Chengdu

466 8560

Novartis Investigative Site, Nagoya

812-8582

Novartis Investigative Site, Fukuoka

371 8511

Novartis Investigative Site, Maebashi

920-8641

Novartis Investigative Site, Kanazawa

514-8507

Novartis Investigative Site, Tsu

565 0871

Novartis Investigative Site, Suita

113 8655

Novartis Investigative Site, Bunkyo Ku

160 8582

Novartis Investigative Site, Shinjuku-ku

160-0023

Novartis Investigative Site, Shinjuku-ku

06351

Novartis Investigative Site, Seoul

06591

Novartis Investigative Site, Seoul

03080

Novartis Investigative Site, Seoul

03722

Novartis Investigative Site, Seoul